Last reviewed · How we verify
Pregabalin 25 MG
Pregabalin 25 MG is a Anticonvulsant Small molecule drug developed by Ajou University School of Medicine. It is currently FDA-approved.
Pregabalin 25 MG is an anticonvulsant medication primarily used to treat neuropathic pain and epilepsy. It is not approved by the FDA, and its development is associated with Ajou University School of Medicine. The drug works by modulating calcium channels in the nervous system, reducing the release of neurotransmitters that cause pain and seizures. Despite its potential benefits, it has several side effects, including dizziness, somnolence, and peripheral edema. The drug's safety profile includes warnings for potential respiratory depression and contraindications in patients with severe renal impairment. Its commercial prospects are uncertain due to the lack of FDA approval.
At a glance
| Generic name | Pregabalin 25 MG |
|---|---|
| Sponsor | Ajou University School of Medicine |
| Drug class | Anticonvulsant |
| Target | α2δ subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Boxed warnings
- Respiratory Depression
Common side effects
Key clinical trials
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
- Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt) (PHASE2)
- The Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture (NA)
- Pregabalin Treatment for RDEB Pain and Itch (PHASE3)
- Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)
- Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)
- Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)
- PROUD Study - Preventing Opioid Use Disorders (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pregabalin 25 MG CI brief — competitive landscape report
- Pregabalin 25 MG updates RSS · CI watch RSS
- Ajou University School of Medicine portfolio CI
Frequently asked questions about Pregabalin 25 MG
What is Pregabalin 25 MG?
Who makes Pregabalin 25 MG?
What drug class is Pregabalin 25 MG in?
What development phase is Pregabalin 25 MG in?
What does Pregabalin 25 MG target?
Related
- Drug class: All Anticonvulsant drugs
- Target: All drugs targeting α2δ subunit of voltage-gated calcium channels
- Manufacturer: Ajou University School of Medicine — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing